Sitagliptin / Metformin hydrochloride Mylan

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

sitagliptin hydrochloride monohydrate, metformin hydrochloride

Available from:

Mylan Ireland Limited

ATC code:

A10BD07

INN (International Name):

sitagliptin hydrochloride monohydrate, metformin hydrochloride

Therapeutic group:

Лекарства, използвани при диабет

Therapeutic area:

Захарен диабет тип 2

Therapeutic indications:

For adult patients with type 2 diabetes mellitus:Sitagliptin/Metformin hydrochloride Mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. Sitagliptin/Metformin hydrochloride Mylan is indicated in combination with a sulphonylurea (i. тройно комбинирано лечение) като допълнение към диета и упражнения при пациенти, недостатъчно контролирани за тяхното максимално переносимой дозата на метформина и сульфонилмочевины. Sitagliptin/Metformin hydrochloride Mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARg agonist. Sitagliptin/Metformin hydrochloride Mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Product summary:

Revision: 2

Authorization status:

упълномощен

Authorization date:

2022-02-16

Patient Information leaflet

                                46
Б. ЛИСТОВКА
47
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПАЦИЕНТА
СИТАГЛИПТИН/МЕТФОРМИНОВ ХИДРОХЛОРИД
MYLAN 50 MG/850
MG ФИЛМИРАНИ ТАБЛЕТКИ
ситаглиптин/метформинов хидрохлорид
(sitagliptin/metformin hydrochloride)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или
медицинска сестра.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
лекарствени реакции, уведомете Вашия
лекар, фармацевт
или медицинска сестра. Това включва и
всички възможни нежелани реакции,
неописани в
тази листовка. Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява
Ситаглиптин/Метформинов хидрохлорид
Mylan и за какво се
използва
2.
Какво трябва да знаете, преди да
приемете Ситаглиптин/Метформинов
хидрохлорид
Mylan
3.
Как да приемате
Ситаглиптин/Метформинов хидрохлорид
Mylan
4.
Възможни нежелани реакци
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Ситаглиптин/Метформинов хидрохлорид
Mylan 50 mg/850 mg филмирани таблетки
Ситаглиптин/Метформинов хидрохлорид
Mylan 50 mg/1 000 mg филмирани таблетки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Ситаглиптин/Метформинов хидрохлорид
Mylan 50 mg/850 mg филмирани таблетки
Всяка таблетка съдържа ситаглиптинов
хидрохлорид монохидрат, еквивалентен
на 50 mg
ситаглиптин (sitagliptin), и 850 mg метформинов
хидрохлорид (metformin hydrochloride).
Ситаглиптин/Метформинов хидрохлорид
Mylan 50 mg/1 000 mg филмирани таблетки
Всяка таблетка съдържа ситаглиптинов
хидрохлорид монохидрат, еквивалентен
на 50 mg
ситаглиптин (sitagliptin), и 1 000 mg
метформинов хидрохлорид (metformin
hydrochloride).
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Филмирана таблетка (таблетка)
Ситаглиптин/Метформинов хидрохлорид
Mylan 50 mg/850 mg филмирани таблетки
Розова таблетка с форма на капсула,
двойноизпъкнала, със скосени ръбове, с
вдлъбнато
релефно означение “M” от едната
страна на таблетката и “SM5” от
другата страна. Размер:
приблизително 20 mm X 10 mm.
Ситаглиптин/Метформинов хидрохлорид
Mylan 50 mg/1 000 mg филмирани таблетк
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 30-05-2023
Public Assessment Report Public Assessment Report Spanish 08-03-2022
Patient Information leaflet Patient Information leaflet Czech 30-05-2023
Public Assessment Report Public Assessment Report Czech 08-03-2022
Patient Information leaflet Patient Information leaflet Danish 30-05-2023
Public Assessment Report Public Assessment Report Danish 08-03-2022
Patient Information leaflet Patient Information leaflet German 30-05-2023
Public Assessment Report Public Assessment Report German 08-03-2022
Patient Information leaflet Patient Information leaflet Estonian 30-05-2023
Public Assessment Report Public Assessment Report Estonian 08-03-2022
Patient Information leaflet Patient Information leaflet Greek 30-05-2023
Public Assessment Report Public Assessment Report Greek 08-03-2022
Patient Information leaflet Patient Information leaflet English 30-05-2023
Public Assessment Report Public Assessment Report English 08-03-2022
Patient Information leaflet Patient Information leaflet French 30-05-2023
Public Assessment Report Public Assessment Report French 08-03-2022
Patient Information leaflet Patient Information leaflet Italian 30-05-2023
Public Assessment Report Public Assessment Report Italian 08-03-2022
Patient Information leaflet Patient Information leaflet Latvian 30-05-2023
Public Assessment Report Public Assessment Report Latvian 08-03-2022
Patient Information leaflet Patient Information leaflet Lithuanian 30-05-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-05-2023
Public Assessment Report Public Assessment Report Lithuanian 08-03-2022
Patient Information leaflet Patient Information leaflet Hungarian 30-05-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 30-05-2023
Public Assessment Report Public Assessment Report Hungarian 08-03-2022
Patient Information leaflet Patient Information leaflet Maltese 30-05-2023
Public Assessment Report Public Assessment Report Maltese 08-03-2022
Patient Information leaflet Patient Information leaflet Dutch 30-05-2023
Public Assessment Report Public Assessment Report Dutch 08-03-2022
Patient Information leaflet Patient Information leaflet Polish 30-05-2023
Public Assessment Report Public Assessment Report Polish 08-03-2022
Patient Information leaflet Patient Information leaflet Portuguese 30-05-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 30-05-2023
Public Assessment Report Public Assessment Report Portuguese 08-03-2022
Patient Information leaflet Patient Information leaflet Romanian 30-05-2023
Public Assessment Report Public Assessment Report Romanian 08-03-2022
Patient Information leaflet Patient Information leaflet Slovak 30-05-2023
Public Assessment Report Public Assessment Report Slovak 08-03-2022
Patient Information leaflet Patient Information leaflet Slovenian 30-05-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 30-05-2023
Public Assessment Report Public Assessment Report Slovenian 08-03-2022
Patient Information leaflet Patient Information leaflet Finnish 30-05-2023
Public Assessment Report Public Assessment Report Finnish 08-03-2022
Patient Information leaflet Patient Information leaflet Swedish 30-05-2023
Public Assessment Report Public Assessment Report Swedish 08-03-2022
Patient Information leaflet Patient Information leaflet Norwegian 30-05-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 30-05-2023
Patient Information leaflet Patient Information leaflet Icelandic 30-05-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 30-05-2023
Patient Information leaflet Patient Information leaflet Croatian 30-05-2023
Public Assessment Report Public Assessment Report Croatian 08-03-2022